Related Experiment Video
Updated: Aug 13, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.0K
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study
Andrew Blauvelt1, David M Pariser2, Stephen Tyring3
1Oregon Medical Research Center, Portland, OR, USA.
Journal of Dermatological Science
|January 23, 2023
Summary
Secukinumab effectively treats plaque psoriasis by normalizing inflammation markers. Early molecular changes at 12 weeks predict sustained clinical improvement over 52 weeks.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Secukinumab, an IL-17A inhibitor, shows efficacy in moderate-to-severe plaque psoriasis.
- It normalizes molecular and histopathologic markers of psoriasis.
Purpose of the Study:
- To assess secukinumab's effects on psoriasis clinical signs.
- To evaluate its impact on psoriatic inflammation markers over 52 weeks.
Main Methods:
- The ObePso-S study randomized patients to secukinumab or placebo for 52 weeks.
- Clinical responses (PASI90, IGA) and skin biopsies (K16, gene expression) were analyzed.
- Placebo patients switched to secukinumab at Week 12.
Main Results:
- 55.8% and 59.6% of secukinumab patients achieved PASI90 at Weeks 12 and 52.
- K16 absence correlated with PASI90 response, indicating reduced inflammation.
- Early inflammatory gene expression control predicted Week 52 clinical outcomes.
Conclusions:
- Sustained secukinumab response links to normalized K16 and inflammation markers.
- Early molecular anti-inflammatory effects predict later clinical success.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
230
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
230
01:30Inflammatory Bowel Disease II: Crohn's Disease
333
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
333
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
205
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
205
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
385
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
385
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
181
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
181